Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy

Patients who achieve a long-term response after first-line TKI therapy could have a favorable prognosis with second-line mTT.